Effect of nettle extract and exercise in type 2 diabetic patients

Study of the effect of hydroalcoholic extract of nettle (Urtica dioica L.) and aerobic exercise on oxidative stress in type 2 diabetic patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015031021412N1

Enrollment

Registered

2015-04-11

Start date

2014-02-18

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus type 2. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Control group: patients with type 2 diabetes (24 women) which will not undergo any treatment. Intervention 2: Intervention group patients with type 2 diabetes during 8 weeks will recei

Treatment - Drugs

Control group: patients with type 2 diabetes (24 women) which will not undergo any treatment.

Intervention group patients with type 2 diabetes during 8 weeks will receive 5cc of hydro alcoholic nettle extract in 3 portions a day.

Intervention group with aerobic exercise during 8 weeks will receive 5cc of hydro alcoholic nettle extract in 3 portions a day.

Eligibility

Sex/Gender

Female

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: female gender over the age of 50 years old; HbA1c levels equal or less than 10%; common diabetes drugs usage (Metformin and Glibenclamide); patients with triglyceride levels less than 400 mg dL-1. Exclusion criteria: patients with cardiovascular; renal; liver; thyroid diseases; infections; allergies; angina; the regular use of NSAIDs (Non-Steroid Anti Inflammatory Drugs); warfarin; alcohol; herbal tea; dietary supplements; insulin injection.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FPG. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test.;TG. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test.;SOD. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test.;NO. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test.;SGPT. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test.;SGOT. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test.;HDL. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test.;LDL. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test.	—

Measure

Time frame

FPG. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test.;TG. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test.;SOD. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test.;NO. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test.;SGPT. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test.;SGOT. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test.;HDL. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test.;LDL. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hamid Kalalian Moghadam

Shahroud University of Medical Sciences

h.kalalian@shmu.ac.ir+98 23 3239 5054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026